JP2023168448A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023168448A5 JP2023168448A5 JP2023170155A JP2023170155A JP2023168448A5 JP 2023168448 A5 JP2023168448 A5 JP 2023168448A5 JP 2023170155 A JP2023170155 A JP 2023170155A JP 2023170155 A JP2023170155 A JP 2023170155A JP 2023168448 A5 JP2023168448 A5 JP 2023168448A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- cbd
- aeds
- extract
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1718862.4 | 2017-11-15 | ||
| GB1718862.4A GB2568471B (en) | 2017-11-15 | 2017-11-15 | Use of cannabinoids in the treatment of epilepsy |
| PCT/GB2018/053315 WO2019097238A1 (en) | 2017-11-15 | 2018-11-15 | Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome |
| JP2020526576A JP7391019B2 (ja) | 2017-11-15 | 2018-11-15 | レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526576A Division JP7391019B2 (ja) | 2017-11-15 | 2018-11-15 | レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023168448A JP2023168448A (ja) | 2023-11-24 |
| JP2023168448A5 true JP2023168448A5 (https=) | 2024-03-07 |
| JP7723711B2 JP7723711B2 (ja) | 2025-08-14 |
Family
ID=60788456
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526576A Active JP7391019B2 (ja) | 2017-11-15 | 2018-11-15 | レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用 |
| JP2023170155A Active JP7723711B2 (ja) | 2017-11-15 | 2023-09-29 | レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526576A Active JP7391019B2 (ja) | 2017-11-15 | 2018-11-15 | レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210169824A1 (https=) |
| EP (2) | EP4487860A3 (https=) |
| JP (2) | JP7391019B2 (https=) |
| KR (1) | KR102786614B1 (https=) |
| CN (1) | CN111629756A (https=) |
| AU (2) | AU2018366443A1 (https=) |
| BR (1) | BR112020009508A2 (https=) |
| CA (1) | CA3082433A1 (https=) |
| DK (1) | DK3710058T3 (https=) |
| ES (1) | ES2991947T3 (https=) |
| FI (1) | FI3710058T3 (https=) |
| GB (1) | GB2568471B (https=) |
| IL (1) | IL274633A (https=) |
| MX (2) | MX2020005147A (https=) |
| RU (1) | RU2020119390A (https=) |
| WO (1) | WO2019097238A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916977D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| GB202009321D0 (en) | 2020-06-18 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| KR102891881B1 (ko) | 2020-07-16 | 2025-11-26 | 주식회사 엘지에너지솔루션 | 듀얼 슬롯 다이 코터 |
| GB2597321A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597304A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome |
| WO2022017936A1 (en) * | 2020-07-20 | 2022-01-27 | GW Research Limited | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597280A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with auriculotemporal syndrome |
| GB202013765D0 (en) | 2020-09-02 | 2020-10-14 | Gw Res Ltd | Method of preparing cannabinoids |
| GB2602019A (en) | 2020-12-15 | 2022-06-22 | Gw Res Ltd | Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof |
| WO2023060024A1 (en) * | 2021-10-04 | 2023-04-13 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders |
| JP2025512495A (ja) | 2022-04-12 | 2025-04-17 | シャッケルフォード・ファーマ・インコーポレーテッド | 発作性障害の治療 |
| WO2024033521A1 (en) | 2022-08-12 | 2024-02-15 | GW Research Limited | Oral solid dosage forms comprising cannabinoids |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2950424C (en) | 2014-05-29 | 2023-03-14 | Insys Pharma, Inc. | Stable cannabinoid formulations |
| US12544389B2 (en) * | 2014-05-29 | 2026-02-10 | Fresh Cut Development, Llc | Stable cannabinoid formulations |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
-
2017
- 2017-11-15 GB GB1718862.4A patent/GB2568471B/en not_active Expired - Fee Related
-
2018
- 2018-11-15 MX MX2020005147A patent/MX2020005147A/es unknown
- 2018-11-15 CN CN201880080175.4A patent/CN111629756A/zh active Pending
- 2018-11-15 EP EP24200897.7A patent/EP4487860A3/en active Pending
- 2018-11-15 AU AU2018366443A patent/AU2018366443A1/en not_active Abandoned
- 2018-11-15 KR KR1020207015573A patent/KR102786614B1/ko active Active
- 2018-11-15 DK DK18808075.8T patent/DK3710058T3/da active
- 2018-11-15 WO PCT/GB2018/053315 patent/WO2019097238A1/en not_active Ceased
- 2018-11-15 FI FIEP18808075.8T patent/FI3710058T3/fi active
- 2018-11-15 EP EP18808075.8A patent/EP3710058B1/en active Active
- 2018-11-15 US US16/764,701 patent/US20210169824A1/en not_active Abandoned
- 2018-11-15 CA CA3082433A patent/CA3082433A1/en active Pending
- 2018-11-15 ES ES18808075T patent/ES2991947T3/es active Active
- 2018-11-15 JP JP2020526576A patent/JP7391019B2/ja active Active
- 2018-11-15 BR BR112020009508-7A patent/BR112020009508A2/pt not_active IP Right Cessation
- 2018-11-15 RU RU2020119390A patent/RU2020119390A/ru unknown
-
2020
- 2020-05-13 IL IL274633A patent/IL274633A/en unknown
- 2020-07-13 MX MX2023012352A patent/MX2023012352A/es unknown
-
2023
- 2023-09-29 JP JP2023170155A patent/JP7723711B2/ja active Active
-
2024
- 2024-08-28 AU AU2024216397A patent/AU2024216397B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023168448A5 (https=) | ||
| FI4061344T3 (fi) | 6-hydroksikannabidioli käytettäväksi lääkkeenä | |
| RU2020119390A (ru) | Применение каннабиноидов при лечении приступов, связанных с синдромом леннокса-гасто | |
| Bharara et al. | Intravenous vitamin C administered as adjunctive therapy for recurrent acute respiratory distress syndrome | |
| AU2025287414A1 (en) | Combinations of cannabinoids and N-acylethanolamines | |
| RU2020127876A (ru) | Применение каннабиноидов в лечении эпилепсии | |
| JP2018514589A5 (https=) | ||
| Garcia et al. | Antiparasitic treatment of neurocysticercosis-The effect of cyst destruction in seizure evolution | |
| JP2014533680A5 (https=) | ||
| JP2018521042A5 (https=) | ||
| JPWO2020109806A5 (https=) | ||
| JPWO2021099781A5 (https=) | ||
| CN119606938B (zh) | 绿原酸在制备预防和治疗主动脉夹层药物中的应用 | |
| Hosseinimehr et al. | Hesperidin inhibits cyclophosphamide-induced tumor growth delay in mice | |
| JPWO2021099775A5 (https=) | ||
| Jia-Yi et al. | Effect and mechanism of Qishen Yiqi Pills on adriamycin-induced cardiomyopathy in mice | |
| CA3049125A1 (en) | Compositions for use in treating inflammatory bowel diseases and intestinal colitis | |
| JP2015518002A5 (https=) | ||
| Decerf et al. | Can methadone prolong the QT interval? | |
| JP2010505827A5 (https=) | ||
| NZ764569B2 (en) | Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome | |
| Abroug | High-dose pralidoxime for organophosphorus poisoning | |
| Gjermeni et al. | Flecainide‐Associated Cardiogenic Shock in a Patient with Atrial Fibrillation | |
| Zhao et al. | The synergy of vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia | |
| Sullivan | Phase II findings in AD drug trial ‘Not All Bad’ |